Kalderos offers a SaaS drug discount management solution that identifies, checks and resolves non-compliance using models and machine learning to detect inconsistencies overlooked by current methods. Its platform aims to eliminate waste and has served stakeholders across the healthcare system, including providers. The company recently launched a provider-facing Review platform to support 340B-covered entities in their claims review process. Kalderos is led by CEO and co-founder Jeremy Docken. The company plans to use new capital to solidify its point-of-sale solution, expand to directly support patients and other discount types, and explore other financial exchanges in healthcare. It is also planning a 501(c)(3) nonprofit arm intended to help patients access lifesaving medications. Kalderos provides a real-time, compliant, point-of-sale chargeback SaaS solution for the prescription drug market. Its platform combines industry expertise, artificial intelligence, and deep-data libraries to ensure the right discounts are applied to the right transaction. The company released its SaaS platform in 2016 and its software detects problems in the complex financial interplay between pharmacies, insurers, manufacturers and payers. Current customers include seven of the 15 largest drug manufacturers. Led by CEO and co-founder Jeremy Docken, Kalderos intends to use new funding to accelerate market adoption. The company is based in Chicago, IL.

Total raised

$35M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2020